202 related articles for article (PubMed ID: 22882428)
1. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system.
Khan N; Abbas AM; Bazzano LA; Koleva YN; Krousel-Wood M
Aliment Pharmacol Ther; 2012 Oct; 36(8):755-64. PubMed ID: 22882428
[TBL] [Abstract][Full Text] [Related]
2. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose.
Khan N; Abbas AM; Koleva YN; Bazzano LA
Inflamm Bowel Dis; 2013 May; 19(6):1123-9. PubMed ID: 23514878
[TBL] [Abstract][Full Text] [Related]
3. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids.
Bello C; Belaiche J; Louis E; Reenaers C
J Crohns Colitis; 2011 Jun; 5(3):196-202. PubMed ID: 21575881
[TBL] [Abstract][Full Text] [Related]
4. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
5. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
Richter JM; Kushkuley S; Barrett JA; Oster G
Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
[TBL] [Abstract][Full Text] [Related]
6. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD.
Moss AC; Lillis Y; Edwards George JB; Choudhry NK; Berg AH; Cheifetz AS; Horowitz G; Leffler DA
Am J Gastroenterol; 2014 Dec; 109(12):1850-5. PubMed ID: 24913040
[TBL] [Abstract][Full Text] [Related]
7. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis.
Frieri G; Pimpo M; Galletti B; Palumbo G; Corrao G; Latella G; Chiaramonte M; Caprilli R
Dig Liver Dis; 2005 Feb; 37(2):92-6. PubMed ID: 15733520
[TBL] [Abstract][Full Text] [Related]
8. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance.
Elkjaer M
Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851
[TBL] [Abstract][Full Text] [Related]
9. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis.
Lee HJ; Jung ES; Lee JH; Hong SP; Kim TI; Kim WH; Cheon JH
Hepatogastroenterology; 2012; 59(117):1415-20. PubMed ID: 22683958
[TBL] [Abstract][Full Text] [Related]
11. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study.
Gifford AE; Berg AH; Lahiff C; Cheifetz AS; Horowitz G; Moss AC
Am J Gastroenterol; 2013 Feb; 108(2):249-55. PubMed ID: 23295279
[TBL] [Abstract][Full Text] [Related]
12. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database.
Lachaine J; Yen L; Beauchemin C; Hodgkins P
BMC Gastroenterol; 2013 Jan; 13():23. PubMed ID: 23363459
[TBL] [Abstract][Full Text] [Related]
13. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.
Mitra D; Hodgkins P; Yen L; Davis KL; Cohen RD
BMC Gastroenterol; 2012 Sep; 12():132. PubMed ID: 23006789
[TBL] [Abstract][Full Text] [Related]
14. An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements.
Moshkovska T; Stone MA; Clatworthy J; Smith RM; Bankart J; Baker R; Wang J; Horne R; Mayberry JF
Aliment Pharmacol Ther; 2009 Dec; 30(11-12):1118-27. PubMed ID: 19785623
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids.
Garcia-Planella E; Mañosa M; Van Domselaar M; Gordillo J; Zabana Y; Cabré E; López San Román A; Domènech E
Dig Liver Dis; 2012 Mar; 44(3):206-10. PubMed ID: 22079262
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.
Kane SV; Cohen RD; Aikens JE; Hanauer SB
Am J Gastroenterol; 2001 Oct; 96(10):2929-33. PubMed ID: 11693328
[TBL] [Abstract][Full Text] [Related]
17. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis.
Rowe FA; Walker JH; Karp LC; Vasiliauskas EA; Plevy SE; Targan SR
Am J Gastroenterol; 2000 Aug; 95(8):2000-8. PubMed ID: 10950049
[TBL] [Abstract][Full Text] [Related]
18. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease.
Kane S; Becker B; Harmsen WS; Kurian A; Morisky DE; Zinsmeister AR
Am J Gastroenterol; 2012 Feb; 107(2):154-60. PubMed ID: 22306937
[TBL] [Abstract][Full Text] [Related]
19. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.
Hodgkins P; Swinburn P; Solomon D; Yen L; Dewilde S; Lloyd A
Patient; 2012; 5(1):33-44. PubMed ID: 22077619
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis.
Carmody JK; Plevinsky J; Peugh JL; Denson LA; Hyams JS; Lobato D; LeLeiko NS; Hommel KA
Aliment Pharmacol Ther; 2019 Oct; 50(8):911-918. PubMed ID: 31373712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
